Chong Kun Dang Pharmaceutical
Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health
Chong Kun Dang Pharmaceutical is a clinical trial sponsor. It has 12 active clinical trials with 12,190 planned participants, across 14 therapeutic areas. Since 2021 it has completed 87 trials and stopped 0 early.
Trial track record · since 2021
Pipeline · 12 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical is lead sponsor of 12 active clinical trials on ClinicalTrials.gov, with 12,190 planned participants, in Cardiovascular, Dermatology, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 87 trials and stopped 0 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Chong Kun Dang Pharmaceutical; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-30.
Approve Suite is not affiliated with Chong Kun Dang Pharmaceutical.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.